Table 2 Clinical and pathological characteristics of the study sample
From: Androgen receptor expression in a Sri Lankan patient cohort with early breast carcinoma
Clinico-pathological feature | Mean (SD) or Number (Percentage) | |
|---|---|---|
Age | Mean age (years) | 55.46 (11.28) |
Body Mass Index | Mean BMI (kg/m2) | 26.69 (6.24) |
Ethnicity | Sinhalese | 115 (81.6%) |
Tamil | 13 (9.2%) | |
Moor | 13 (9.2%) | |
Menopausal status | Premenopausal | 44 (31.2%) |
Post-menopausal | 97 (68.8%) | |
Parity | Nulliparous | 14 (9.9%) |
Parous | 122 (86.5%) | |
Not available | 5 (3.5%) | |
History of oral contraceptive use | Present | 27 (19.1%) |
Absent | 109 (77.3%) | |
Not available | 5 (3.5%) | |
History of use of hormone replacement therapy | Present | 2 (1.4%) |
Absent | 133 (94.3%) | |
Not available | 6 (4.3%) | |
History of breast feeding | Present | 120 (85.1%) |
Absent | 16 (11.3%) | |
Not available | 5 (3.5%) | |
Family history of breast cancer | Present | 11 (7.8%) |
Absent | 130 (92.2%) | |
TNM stage* | Stage I | 17 (12.1%) |
Stage II | 93 (66.0%) | |
Stage III | 31 (22.0%) | |
Nodal stage* (Lymph nodes were assessed in 128 patients) | N0 | 72 (56.2%) |
N1 | 26 (20.3%) | |
N2 | 14 (10.9%) | |
N3 | 16 (12.5%) | |
Histology type | Ductal | 125 (88.7%) |
Lobular | 6 (4.3%) | |
Mucinous | 3 (2.1%) | |
Micropapillary | 1 (0.7%) | |
Metaplastic | 4 (2.8%) | |
Adenoid cystic | 1 (0.7%) | |
Carcinoma with neuroendocrine features | 1 (0.7%) | |
Histology grade | Grade 1 | 31 (22.0%) |
Grade 2 | 51 (36.2%) | |
Grade 3 | 59 (41.8%) | |
Receptor status | ||
 ER | Positive | 68 (49.3%) |
Negative | 70 (50.7%) | |
 PR | Positive | 75 (53.6%) |
Negative | 65 (46.4%) | |
 HER 2 | Positive | 20 (14.9%) |
Negative | 121 (85.1%) | |
Molecular subtypes | Luminal | 87 (61.7%) |
HER 2 | 17 (12.1%) | |
Triple negative | 37 (26.2%) | |
Type of surgery | Wide – local excision | 22 (15.6%) |
Mastectomy | 119 (84.4%) | |
Type of adjuvant therapy (Specific treatment details were available in 84 patients) | Hormonal treatment | 50 (59.5%) |
Chemotherapy | 32 (38.1%) | |
Trastuzumab | 10 (11.9%) | |
Radiotherapy | 9 (10.7%) | |